CCL2 and metabolic disease: The identification and exploration of biomarkers such as GLP-1, GIP, MCP-1, and IGFBP-7 have provided valuable insights into the complex pathophysiology of metabolic disorders, including type 2 diabetes and obesity [1,2,3,4,5,6,7,8,9].